Metabonomics study of the serum from ovarian cancer patients

Objective: Metabonomics may identify potential metabolite markers for ovarian cancer diagnosis. The authors report a metabonomics study of ovarian cancer serum, aiming to identify a distinct serum metabolome of ovarian cancer with diagnostic potential. Materials and Methods: Serum metabolites from diagnosed ovarian cancer patients and healthy subjects were profiled using gas chromatography coupled with mass spectrometry (GC-MS). Results: Differential metabolites of 36 chemicals were identified with statistical tests of orthogonal partial least-squares-discriminant analysis (VIP > 1.2) and the t-test (p < 0.05), being able to differentiate ovarian cancer patients from the healthy controls. The authors observed an altered metabolome in ovarian cancer patients, including glycolysis and tricarboxylic acid (TCA) cycle, urea cycle, glutamine, fatty acids, and proline metabolism. A panel of three serum metabolite markers, containing beta-alanine, palmitic acid and proline, can differentiate ovarian cancer patients from healthy controls with an area under curve (AUC) of 0.995 in the receiver operating characteristic (ROC) analysis. Conclusion: The present results demonstrated that metabonomics is of great potential for finding a non-invasive diagnostic method for the detection of ovarian cancer.

Metabonomics; Serum; Ovarian cancer; Gas chromatography coupled with mass spectrometry (GC-MS); Principal component analysis (PCA); Partial least-squares-discriminant analysis (OPLS-DA)

[1] American Cancer Society: “Cancer Facts and Figures 2014”. Available at: https://www.cancer.org/content/dam/cancer-org/research/ cancer-facts-and-statistics/annual-cancer-facts-and-figures/2014/ cancer-facts-and-figures-2014.pdf

[2] Zhang S.W., Chen W.Q., Wei W.Q., Li G.L., Li N., Li Y.Q.: “Ovary cancer mortality in China 2004 - 2005: results from the Third National Retrospective Sampling Survey of Death Causes”. zhonghua Yu Fang Yi Xue za zhi, 2010, 44, 418.

[3] Jacobs I.J., Menon U.: “Progress and challenges in screening for early detection of ovarian cancer”. Mol. Cell. Proteomics, 2004, 3, 355.

[4] Whitehouse C., Solomon E.: “Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening”. Gynecol. Oncol., 2003, 88, S152.

[5] Bagan P., Berna P., Assouad J., Hupertan V., Le Pimpec Barthes F., Riquet M.: “Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax”. Eur. Respir. J., 2008, 31, 140.

[6] Sarandakou A., Protonotariou E., Rizos D.: “Tumor markers in biological fluids associated with pregnancy”. Crit. Rev. Clin. Lab. Sci., 2007, 44, 151.

[7] Osman N., O’Leary N., Mulcahy E., Barrett N., Wallis F., Hickey K., et al.: “Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre”. Ir. Med. J., 2008, 101, 245.

[8] Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al.: “Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression”. Nature, 2009, 457, 910.

[9] Denkert C., Budczies J., Kind T., Weichert W., Tablack P., Sehouli J., et al.: “Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors”. Cancer Res., 2006, 66, 10795.

[10] Wu H., Xue R., Lu C., Deng C., Liu T., Zeng H., et al.: “Metabolomics studies of prostate cancer using gas chromatography-mass spectrometery”. Transl. Cancer Res., 2016, 5, 302.

[11] Buckendahl A.C., Budczies J., Fiehn O., Darb-Esfahani S., Kind T., Noske A., et al.: “Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics”. Oncol. Rep., 2011, 25, 1005.

[12] Mal M., Koh P.K., Cheah P.Y., Chan E.C.: “Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue”. Rapid. Commun. Mass. Spectrom., 2009, 23, 487.

[13] Chan E.C., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., et al.: “Metabolic profiling of human colorectal cancer using highresolution magic angle spinning nuclear magnetic resonance (HRMAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS)”. J. Proteome. Res., 2009, 8, 352.

[14] Cheng Y., Li L., Zhu B., Liu F., Wang Y., Gu X., et al.: “Expanded metabolomics approach to profiling endogenous carbohydrates in the serum of ovarian cancer patients”. J. Sep. Sci., 2016, 39, 316.

[15] DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., et al.: “Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis”. Proc. Natl. Acad. Sci. U S A, 2007, 104, 19345.

[16] Locasale J.W., Grassian A.R., Melman T., Lyssiotis C.A., Mattaini K.R., Bass A.J., et al.: “Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis”. Nat. Genet., 2011, 43, 869.

[17] Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., et al.: “Functional genomics reveal that the serine synthesis pathway is essential in breast cancer”. Nature, 2011, 476, 346.

[18] Li L., Xu Y., Yu C.X.: “Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors”. Asian Pac. J. Cancer Prev., 2012, 13, 3265.

[19] Dieplinger H., Ankerst D.P., Burges A., Lenhard M., Lingenhel A., Fineder L., et al.: “Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer”. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 1127.

[20] Lai C.Q., Parnell L.D., Ordovas J.M.: “Ordovas, The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk”. Curr. Opin. Lipidol., 2005, 16, 153.